Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 1 718 GBX 4.5% Market Closed
Market Cap: 1.1B GBX
Have any thoughts about
Genus PLC?
Write Note

Relative Value

The Relative Value of one GNS stock under the Base Case scenario is 2 668.85 GBX. Compared to the current market price of 1 718 GBX, Genus PLC is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GNS Relative Value
Base Case
2 668.85 GBX
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
83
Median 3Y
2.6
Median 5Y
3.2
Industry
7.7
Forward
1.6
vs History
7
vs Industry
5
Median 3Y
48.4
Median 5Y
56.9
Industry
22.7
Forward
23.4
vs History
52
vs Industry
7
Median 3Y
44.6
Median 5Y
44
Industry
21.6
vs History
66
vs Industry
1
Median 3Y
112.1
Median 5Y
97.7
Industry
25.2
vs History
85
vs Industry
45
Median 3Y
2.9
Median 5Y
3.4
Industry
2.5
vs History
84
vs Industry
70
Median 3Y
2.9
Median 5Y
3.4
Industry
7.7
Forward
2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9
vs History
84
vs Industry
8
Median 3Y
17.9
Median 5Y
22.1
Industry
4.2
Forward
11.9
vs History
79
vs Industry
5
Median 3Y
31.8
Median 5Y
37.2
Industry
4.1
Forward
18.3
vs History
36
vs Industry
6
Median 3Y
48.1
Median 5Y
46
Industry
5.7
vs History
7
vs Industry
2
Median 3Y
95.9
Median 5Y
95.9
Industry
3.6
vs History
77
vs Industry
53
Median 3Y
2
Median 5Y
2.5
Industry
4.6

Multiples Across Competitors

GNS Competitors Multiples
Genus PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Genus PLC
LSE:GNS
1.1B GBP 1.7 143.6 13.5 25.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
UK
Genus PLC
LSE:GNS
Average P/E: 197.5
143.6
807%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Genus PLC
LSE:GNS
Average EV/EBITDA: 16.7
13.5
35%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
UK
Genus PLC
LSE:GNS
Average EV/EBIT: 22.9
25.2
78%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top